TOMS Capital Shakes Up Kenvue: Sale or Split on the Horizon?

TOMS Capital pushes for Kenvue sale / Bloomberg Hedge Fund’s Bold Move Sparks Urgency for Kenvue’s Future Kenvue Faces New Pressure from TOMS Capital Investment Management TOMS Capital Investment Management, a prominent New York based hedge fund, has taken a significant stake in Kenvue (NYSE:KVUE), the Band Aid and Tylenol maker, and is aggressively pushing for a full sale or strategic asset separation, according to Bloomberg News, citing sources familiar with the matter. This development follows Kenvue’s recent settlement with activist investor Starboard Value, signaling a turbulent period for the consumer health giant spun off from Johnson & Johnson (NYSE:JNJ) in 2023. While the exact size of TOMS Capital’s stake in Kenvue remains undisclosed, adding an element of mystery to their influence, their move underscores a growing investor impatience with the company’s trajectory, particularly in its underperforming skin health and beauty segment featuring brands like Neutroge...